Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
July 9, 2025
Bavarian Nordic has secured a major contract exceeding DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European nation in 2025, reinforcing efforts to bolster public health security amid rising biological threats. The MVA-BN vaccine, already approved across multiple global markets, serves as a cornerstone for both mpox outbreak response and smallpox preparedness. This order brings Bavarian Nordic’s 2025 public preparedness contracts to over DKK 3 billion. CEO Paul Chaplin emphasized the strategic importance of vaccine readiness in strengthening geopolitical resilience, highlighting continued EU and global partnerships to ensure access to medical countermeasures in a volatile health landscape.
Bavarian Nordic has announced a contract valued at over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European country, with delivery scheduled for 2025. The deal signals continued investment in national biological threat preparedness amid mounting geopolitical and epidemic concerns. The MVA-BN vaccine, approved across the U.S., EU, Canada, and several other countries under names like JYNNEOS® and IMVANEX®, is a non-replicating vaccine originally developed in partnership with the U.S. government to provide safe immunization even for immunocompromised individuals.
This latest contract adds to Bavarian Nordic’s expanding public preparedness portfolio, bringing the total value of secured contracts to more than DKK 3 billion—squarely within the company's 2025 guidance of DKK 3,000–4,000 million. Company leadership confirmed that total revenue projections (DKK 5,700–6,700 million) and EBITDA margin (26–30%) remain unchanged.
CEO Paul Chaplin framed the contract as a strategic move by European governments to enhance public health resilience. “Biological preparedness is increasingly seen as a pillar of national and regional security,” he stated, underscoring the vaccine’s dual utility in managing mpox outbreaks and defending against potential smallpox threats.
The order reflects a broader shift toward sustained pandemic preparedness, not just for present outbreaks but for future threats with high-impact potential. With the World Health Organization maintaining mpox as a public health emergency of international concern and the risk of emerging or reemerging pathogens growing, MVA-BN’s versatility offers a critical layer of protection.
Bavarian Nordic’s expanding contracts, both within and outside Europe, illustrate the increasing recognition of long-term public health infrastructure as a strategic priority. As vaccine stockpiling becomes central to national security planning, MVA-BN remains a foundational asset in the global health security toolkit.